Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.

You may also be interested in...



Financing In Brief

Pfizer raises commercial bar with Toviaz YourWay program: Pfizer initiated its patient support program, YourWay, for its new overactive bladder treatment Toviaz (fesoterodine fumarate) as of June 2, the pharma announces. "We haven't done anything like this to date in the [OAB] category," Pfizer senior director of marketing Jim Maffezzoli, who oversees Toviaz, said in an interview. Pfizer launched Toviaz into an already-crowded OAB market in April, after FDA approval last fall (1"The Pink Sheet" DAILY, Nov. 3, 2008). The drug maker is positioning the YourWay plan as a means to improve patient compliance by supplementing treatment with information about diet, exercise, setting personal goals and the treatment itself; compliance is a major issue for OAB treatments. Studies are ongoing to evaluate the plan's impact, Pfizer said. Pfizer says payers already are responding to YourWay. Currently, Pfizer has an OAB awareness ad campaign on air with plans for branded direct-to-consumer advertising later this year. It is detailing the drug through its primary care business unit, which recently reorganized into a regional commercial model, which is similar, at least superficially, to steps taken by many of its peers

Financing In Brief

Pfizer raises commercial bar with Toviaz YourWay program: Pfizer initiated its patient support program, YourWay, for its new overactive bladder treatment Toviaz (fesoterodine fumarate) as of June 2, the pharma announces. "We haven't done anything like this to date in the [OAB] category," Pfizer senior director of marketing Jim Maffezzoli, who oversees Toviaz, said in an interview. Pfizer launched Toviaz into an already-crowded OAB market in April, after FDA approval last fall (1"The Pink Sheet" DAILY, Nov. 3, 2008). The drug maker is positioning the YourWay plan as a means to improve patient compliance by supplementing treatment with information about diet, exercise, setting personal goals and the treatment itself; compliance is a major issue for OAB treatments. Studies are ongoing to evaluate the plan's impact, Pfizer said. Pfizer says payers already are responding to YourWay. Currently, Pfizer has an OAB awareness ad campaign on air with plans for branded direct-to-consumer advertising later this year. It is detailing the drug through its primary care business unit, which recently reorganized into a regional commercial model, which is similar, at least superficially, to steps taken by many of its peers

Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?

Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)

Related Content

Topics

UsernamePublicRestriction

Register

PS067071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel